Natalie R. Linendoll
Natalie Linendoll is counsel in the firm’s life sciences group, where her practice focuses on mergers and acquisitions, licensing and collaboration transactions, service and outsourcing relationships and manufacturing and supply arrangements. Her clients are primarily companies in the biotech, medical device and pharmaceutical industries. In addition to transactional work, Natalie also regularly counsels companies on a range of corporate governance and commercial matters.
Natalie rejoined Ropes & Gray in 2015. Prior to rejoining the firm, Natalie served as general counsel at Razorfish, a digital media company. She also served as an Army officer for five years prior to law school.
- Represented Amwell in its acquisition of Aligned Telehealth, a telepsychiatry business on pace to become the largest U.S. provider of on-demand telepsychiatry consults in emergency rooms and acute hospital medical floors.
- Represented Pfizer in its $130 million acquisition of two meningitis vaccines from GlaxoSmithKline.
- Represented Genzyme Corporation in connection with the acquisition of Caprelsa®, a rare disease therapy to treat symptomatic or progressive medullary thyroid carcinoma, from AstraZeneca.
- Represented Heptares Therapeutics in a licensing and product development agreement with Teva Pharmaceuticals to exploit small molecule CGRP antagonists discovered by Heptares for the treatment of migraine headaches.
- Represented Johnson & Johnson in connection with the acquisition of a leading manufacturer of orthopedic implants for small bone fixation.
- Represented Becton Dickinson on the divestiture of its vertebral augmentation business to Stryker.
- Represented Becton Dickinson on the divestiture of its sterile injectable business to Fresenius Kabi.
- Represented Pfizer in its acquisition of AstraZeneca’s late-stage small molecule anti-infective business.
- Represented Magenta Therapeutics in its license from Novartis of a clinical-stage program to support the use of stem cell transplantation in a variety of disease settings.
- Represented Hugel Inc. (a Bain portfolio company) in its establishment of a joint venture company with Croma-Pharma GmbH for the development and commercialization of aesthetic pharmaceutical products in the United States, Canada, Australia and New Zealand.
- Co-author, “Life Sciences U.S. Trends and Developments,” Chambers Global Practice Guide 2021 chapter (April 2021)
- JD, magna cum laude, Georgetown University Law Center, 2006
- BS, United States Military Academy at West Point, 1996
Admissions / Qualifications
- District of Columbia, 2008
- Massachusetts, 2007